Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

201. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials

Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials Kronenberg F, Fugh-Berman A Authors' objectives To review studies of complementary and alternative medicines (CAM) used for menopausal symptoms. Searching MEDLINE (from January 1966 (...) , red clover, dong quai, evening primrose oil, ginseng and Chinese herb mixture), dietary phytoestrogens (soy and soy extracts) and other CAM therapies (vitamin E, behavioural therapies, wild yam and progesterone creams). Participants included in the review Studies investigating women with menopausal symptoms were eligible. Studies examining single symptoms or conditions that are clearly associated with menopause were excluded. Outcomes assessed in the review The inclusion criteria were not defined

DARE.2002

202. Menopausal Combined Hormone Therapy Update

Menopausal Combined Hormone Therapy Update [46] Menopausal Combined Hormone Therapy Update | Therapeutics Initiative Independent Healthcare Evidence > > [46] Menopausal Combined Hormone Therapy Update The Women’s Health Initiative (WHI) trial is a striking example of how scientific evidence can improve prescribing practice. Therapeutics Letter 30 reviewed the evidence on hormone replacement therapy in 1999. Evidence then available showed that long-term estrogen/progestin therapy to prevent (...) cardiovascular disease for menopausal women with previous myocardial infarction would cause more harm than good. This conclusion was based on data from the Heart and Estrogen/Progestin Replacement Study (HERS) randomized controlled trial (RCT). In July 2002 the follow-up of the HERS trial (HERS II) and the WHI were published. These two trials strengthen the evidence against using combined hormone therapy to prevent cardiovascular disease. WHI/HERS II details Population of women: WHI enrolled 16,608 healthy

Therapeutics Letter2002

204. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis.

Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. BACKGROUND: Due to their known effects on bone metabolism, vitamin D and related compounds have been proposed for the prevention of osteoporosis and fractures. OBJECTIVES: To determine the effects of supplementation with Vitamin D or a Vitamin D analogue in the prevention of fractures of the axial and appendicular skeleton in elderly men or women with involutional or post (...) -menopausal osteoporosis. SEARCH STRATEGY: We searched MEDLINE, EMBASE, CINAHL, LILACS, CABNAR, BIOSIS, HEALTHSTAR, Current Contents, The Cochrane Database of Systematic Reviews, the Cochrane Musculoskeletal Injuries Group trials register, and bibliographies of identified trials and reviews. Date of the most recent search: September 2000. SELECTION CRITERIA: Any randomised or quasi-randomised trial which compared vitamin D or a vitamin D analogue, either alone or in combination with calcium

Cochrane2001

205. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Agrawal R, Holmes J, Jacobs H S Authors' objectives To re-analyse the results of using (...) follicle-stimulating hormone (FSH) and human menopausal gonadotropin (hMG) during in vitro fertilisation (IVF) treatment, taking into account the different protocols of administration of superactive gonadotropin-releasing hormone (GnRH) analogues (short, long protocol, or no GnRH analog). Searching The authors searched MEDLINE from January 1985 to 1999 using a combination of the keywords 'FSH', 'LH', 'hMG', 'gonadotropins', 'IVF' and 'comparison'. Review articles and abstracts of major scientific meetings and conference

DARE.2000

206. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.

Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. 10770146 2000 04 27 2000 04 27 2016 10 17 0098-7484 283 14 2000 Apr 12 JAMA JAMA Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. 1845-52 Lipoprotein(a) [Lp(a)] has been identified as an independent risk factor for coronary heart disease (CHD) events. However, few data exist on the clinical importance of Lp(a) lowering

JAMA2000

207. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis.

Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. BACKGROUND: Due to their known effects on bone metabolism, Vitamin D and related compounds have been proposed for the prevention of osteoporosis and fractures. OBJECTIVES: To determine the effects of supplementation with Vitamin D or a Vitamin D analogue in the prevention of fractures of the axial and appendicular skeleton in elderly men or women with involutional or post (...) -menopausal osteoporosis. SEARCH STRATEGY: We searched MEDLINE, EMBASE, BIOSIS, CINAHL, HealthPLAN, Dissertation Abstracts, Index to UK Theses, Current Contents, and bibliographies of identified trials and reviews. Trials were also obtained from the Cochrane Musculoskeletal Injuries Group trials register. Date of the most recent search: December 1995. SELECTION CRITERIA: Any randomised or quasi-randomised trial which compared Vitamin D or a Vitamin D analogue, either alone or in combination with calcium

Cochrane2000

208. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome.

Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. BACKGROUND: The risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) are increased in women with clomiphene resistance WHO group 2 dysfunction undergoing ovulation induction as well as the risk of spontaneous abortion if conception takes place. Semi-purified preparations of FSH have been developed in an effort to reduce (...) the impact of exogenous LH, relatively high levels of which are present in human menopausal gonadotropin (hMG). Ovulation induction in women with clomiphene resistant WHO group 2 dysfunction who often have clinical features of polycystic ovarian syndrome (PCOS), is a major challenge. The risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) are increased in this population. There also appears to be an increased risk of spontaneous abortion in those who conceive, perhaps associated

Cochrane2000

209. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.

Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. BACKGROUND: Hormone replacement therapy (HRT) is commonly prescribed to treat menopausal symptoms and to prevent post-menopausal bone loss. However, many women are concerned about hormonal replacement therapy because they believe that such treatment will result in weight gain. The effect of HRT on weight and body fat distribution has not yet been examined (...) at menopause. (ABSTRACT TRUNCATED)

Cochrane2000

210. Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women

Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Morley D C, Wheatley T Authors' objectives (...) . Studies that focused on an exercise, pharmaceutical or nutritional component without reference to an educational component were excluded. Participants included in the review Healthy post-menopausal women with untreated osteoporosis or significant osteopenia requiring health care intervention. Most of the women included in the review were aged 50-75 years. Outcomes assessed in the review All outcome measures were included, with emphasis on the following: knowledge about osteoporosis and related issues

DARE.1999

211. Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke]

Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Oger E, Scarabin P Y Authors (...) : The authors state that only a randomised controlled trial will prove causation, rather than association, between HRT and the risk of ischaemic stroke. There is also a need to investigate the transdermal administration of HRT. Bibliographic details Oger E, Scarabin P Y. Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Annales d'Endocrinologie 1999; 60(3): 232-241 PubMedID Indexing Status Subject

DARE.1999

212. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.

Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. 10334256 1999 06 04 1999 06 04 2015 06 16 0140-6736 353 9164 1999 May 08 Lancet (London, England) Lancet Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. 1574-8 The benefit of oestrogen therapy for menopause symptoms is well recognised. However, the means of delivery (...) groups. S21400 was thought to be effective and convenient by the patients, and compliance was high. Intranasally administered 17beta-oestradiol is significantly better than placebo; its effectiveness at reducing menopausal symptoms is similar to that of oral oestradiol and is also well-tolerated. Intranasal administration avoids first-pass metabolism and provides a reproducible, easily adjustable dosing mechanism that represents a new option for hormone replacement therapy. Studd J J Chelsea

Lancet1999

213. Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis

Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Macedo J M, Macedo C R, Elkis H, De Oliveira I R Authors' objectives To compare the effect of three groups of anti-resorptive drugs in post-menopausal osteoporosis. Searching MEDLINE was searched from 1983 to 1995 (keywords given). Source (...) references of retrieved articles were analysed. Study selection Study designs of evaluations included in the review Randomised controlled trials including a placebo arm, in which treatment and follow-up lasted at least a year. Specific interventions included in the review The inclusion criteria stated oestrogens, calcitonins, biphosphonates and placebo. Estradiol valerate and 17-beta-estradiol were specifically mentioned in the review. Participants included in the review Patients with post-menopausal

DARE.1998

214. WITHDRAWN: Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles.

WITHDRAWN: Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles. BACKGROUND: Both human menopausal gonadotropin (hMG) and human follicle stimulating hormone (hFSH) have been used successfully for ovarian stimulation, but the relative importance of FSH and luteinizing hormone (LH) in follicular growth and maturation has been the subject of much debate. OBJECTIVES: To conduct a systematic overview of available data comparing FSH

Cochrane1996

215. WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome.

WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. BACKGROUND: The risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) are increased in women with clomiphene resistance WHO group 2 dysfunction undergoing ovulation induction as well as the risk of spontaneous abortion if conception takes place. Semi-purified preparations of FSH have been developed in an effort (...) to reduce the impact of exogenous LH, relatively high levels of which are present in human menopausal gonadotropin (hMG). Ovulation induction in women with clomiphene resistant WHO group 2 dysfunction who often have clinical features of polycystic ovarian syndrome (PCOS), is a major challenge. The risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) are increased in this population. There also appears to be an increased risk of spontaneous abortion in those who conceive, perhaps

Cochrane1996

216. Pathological complications of menopause. IPE-95/03 (Public report)

Pathological complications of menopause. IPE-95/03 (Public report) Pathological complications of menopause. IPE-95/03 (Public report) Pathological complications of menopause. IPE-95/03 (Public report) Sez A, Conde J, Ruiz F, Cuadrado C, Saiz J, Sancho J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sez A, Conde J, Ruiz F, Cuadrado C (...) , Saiz J, Sancho J. Pathological complications of menopause. IPE-95/03 (Public report) Agencia de Evaluacion de Tecnologias Sanitarias (AETS). 1995 Authors' objectives According to the recent Royal Decree (Real Decreto) which establishes the basic public coverage of health care, pathological complications of menopause must be specifically covered. The issue raised by the Ministry of Health is to establish the content of this definition and the necessity to find a specific build-up, procedures

Health Technology Assessment (HTA) Database.1995

217. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis

Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis Daya S, Gunby J, Hughes E G, Collins J A, Sagle M A Authors' objectives To conduct a systematic overview of available data comparing (...) follicle-stimulating hormone (FSH) with human menopausal gonadotropin (hMG) in in vitro fertilisation (IVF) cycles and gamete intra-fallopian transfer (GIFT) cycles. Searching MEDLINE was searched from 1975 to 1993 using MeSH terms (terms given). Bibliographies of relevant publications and review articles were scanned and abstracts of major scientific meetings from 1983 to 1993 were handsearched. Authors of relevant abstracts were contacted as were peer reviewers. Study selection Study designs of evaluations included

DARE.1995

218. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing.

Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. 8136666 1994 04 25 1994 04 25 2016 11 23 0959-8138 308 6927 1994 Feb 19 BMJ (Clinical research ed.) BMJ Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. 501-3 To evaluate the efficacy of gamolenic acid provided by evening primrose oil in treating hot flushes and sweating associated with the menopause. Randomised, double blind, placebo controlled study. District general hospital (...) and teaching hospital. 56 menopausal women suffering hot flushes at least three times a day. Four capsules twice a day of 500 mg evening primrose oil with 10 mg natural vitamin E or 500 mg liquid paraffin for six months. Change in the number of hot flushes or sweating episodes a month. 56 diaries were analysed, 28 from women taking gamolenic acid and 28 from those taking placebo. Only 18 women given gamolenic acid and 17 given placebo completed the trial. The mean (SE) improvement in the number of flushes

BMJ1994 Full Text: Link to full Text with Trip Pro

219. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women

The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women Smith T J, Hillner B E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Adjuvant tamoxifen with or without chemotherapy for early breast cancer in pre-menopausal women. Type of intervention Secondary prevention. Economic study type Cost-effectiveness and cost-utility analysis. Study population Women aged 45 years with early breast cancer, eligible for trials of alternative cancer treatments included in the review

NHS Economic Evaluation Database.1993

220. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause.

Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. 4047104 1985 10 30 1985 10 30 2013 11 21 0028-4793 313 16 1985 Oct 17 The New England journal of medicine N. Engl. J. Med. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. 973-5 To elucidate the effect of smoking on estrogen metabolism, we examined 136 postmenopausal women treated for one year with one of three different doses (...) Menopause Middle Aged Norethindrone analogs & derivatives therapeutic use Osteoporosis etiology Smoking 1985 10 17 1985 10 17 0 1 1985 10 17 0 0 ppublish 4047104 10.1056/NEJM198510173131602

NEJM1985